553 related articles for article (PubMed ID: 28886946)
1. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
Woo EJ; Moro PL; Cano M; Jankosky C
Vaccine; 2017 Oct; 35(42):5618-5621. PubMed ID: 28886946
[TBL] [Abstract][Full Text] [Related]
2. Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system.
Woo EJ; Moro PL
Vaccine; 2021 Mar; 39(13):1812-1817. PubMed ID: 33678452
[TBL] [Abstract][Full Text] [Related]
3. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
[TBL] [Abstract][Full Text] [Related]
4. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.
Halsey NA; Griffioen M; Dreskin SC; Dekker CL; Wood R; Sharma D; Jones JF; LaRussa PS; Garner J; Berger M; Proveaux T; Vellozzi C; ; Broder K; Setse R; Pahud B; Hrncir D; Choi H; Sparks R; Williams SE; Engler RJ; Gidudu J; Baxter R; Klein N; Edwards K; Cano M; Kelso JM
Vaccine; 2013 Dec; 31(51):6107-12. PubMed ID: 24120547
[TBL] [Abstract][Full Text] [Related]
5. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M
Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795
[TBL] [Abstract][Full Text] [Related]
6. Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.
Moro PL; Harrington T; Shimabukuro T; Cano M; Museru OI; Menschik D; Broder K
Vaccine; 2013 Oct; 31(43):4984-7. PubMed ID: 23994022
[TBL] [Abstract][Full Text] [Related]
7. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
[TBL] [Abstract][Full Text] [Related]
8. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.
Vellozzi C; Broder KR; Haber P; Guh A; Nguyen M; Cano M; Lewis P; McNeil MM; Bryant M; Singleton J; Martin D; DeStefano F
Vaccine; 2010 Oct; 28(45):7248-55. PubMed ID: 20850534
[TBL] [Abstract][Full Text] [Related]
9. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
10. The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study.
Daley MF; Clarke CL; Glanz JM; Xu S; Hambidge SJ; Donahue JG; Nordin JD; Klein NP; Jacobsen SJ; Naleway AL; Jackson ML; Lee G; Duffy J; Weintraub E
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):59-68. PubMed ID: 29148124
[TBL] [Abstract][Full Text] [Related]
11. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
[TBL] [Abstract][Full Text] [Related]
12. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.
Haber P; Moro PL; Lewis P; Woo EJ; Jankosky C; Cano M
Vaccine; 2016 May; 34(22):2507-12. PubMed ID: 27015735
[TBL] [Abstract][Full Text] [Related]
13. Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.
Haber P; Moro PL; Cano M; Lewis P; Stewart B; Shimabukuro TT
Vaccine; 2015 Apr; 33(16):1987-92. PubMed ID: 25678241
[TBL] [Abstract][Full Text] [Related]
14. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
[TBL] [Abstract][Full Text] [Related]
15. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
[TBL] [Abstract][Full Text] [Related]
16. Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
Woo EJ; Moro PL
Vaccine; 2022 Feb; 40(7):1026-1030. PubMed ID: 35031148
[TBL] [Abstract][Full Text] [Related]
17. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.
Moro PL; Woo EJ; Marquez P; Cano M
Vaccine; 2020 Aug; 38(37):5923-5926. PubMed ID: 32709434
[TBL] [Abstract][Full Text] [Related]
18. Post-Licensure Surveillance of Trivalent Live-Attenuated Influenza Vaccine in Children Aged 2-18 Years, Vaccine Adverse Event Reporting System, United States, July 2005-June 2012.
Haber P; Moro PL; Cano M; Vellozzi C; Lewis P; Woo EJ; Broder K
J Pediatric Infect Dis Soc; 2015 Sep; 4(3):205-13. PubMed ID: 26407428
[TBL] [Abstract][Full Text] [Related]
19. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
Haber P; Moro PL; Ng C; Lewis PW; Hibbs B; Schillie SF; Nelson NP; Li R; Stewart B; Cano MV
Vaccine; 2018 Jan; 36(4):559-564. PubMed ID: 29241647
[TBL] [Abstract][Full Text] [Related]
20. Allergic reactions after egg-free recombinant influenza vaccine: reports to the US Vaccine Adverse Event Reporting System.
Woo EJ
Clin Infect Dis; 2015 Mar; 60(5):777-80. PubMed ID: 25428412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]